Oral administration of pneumoccal antigens

US6231870A · kind A · utility

Assignee

• THE UAB RESEARCH FOUNDATION · US

Inventors

• David E. Briles · Birmingham, US
• Larry S. McDaniel · Birmingham, US
• Masafumi Yamamoto · Birmingham, US
• Hiroshi Kiyono · Tokyo, JP

Key dates

• Filing date: Jun 2, 1995
• Grant date: May 15, 2001
• Expiry date: Jun 2, 2015

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Oral or peroral administration, including intragastrically, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with an adjuvant such as cholera toxin provides protection in a host, animal or human, against pneumococcal infection, including colonization, and systemic infection, such as sepsis. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.